CYP2B6 and metabolic disease: Thus, SJW treatment in metabolic diseases, primarily aimed at inhibiting the basic inflammatory state, would have the additional advantage of counterbalancing the aforementioned repression of the P-450 drug metabolizing system and concomitantly reducing the overall risk of abnormal drug interactions.